Amarantus Bioscience Holdings Inc (AMBS)

[zoomboom]

News Out : Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS


SAN FRANCISCO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary Cutanogen Corporation was issued a patent in Hong Kong entitled "Surgical device for skin therapy or testing" covering the method of producing Engineered Skin Substitute for the treatment of skin-related conditions and/or testing of potential treatments for skin-related conditions. The patent includes claims relating to the method of manufacturing ESS, methods for adding melanocytes to ESS to improve skin color-matching for patients, and methods for genetically-modifying ESS. Cutanogen Corporation is currently in the planning phases for the pivotal development of ESS for the treatment of life-threatening pediatric severe burns based upon data published in the peer-reviewed medical Journal of Burn Care & Research entitled "Randomized, Paired-Site Comparison of Autologous Engineered Skin Substitutes and Split-Thickness Skin Graft for Closure of Extensive, Full-Thickness Burns".

https://finance.yahoo.com/news/amarantus-subsidiary-cutanogen-corporation-announces-144500433.html